PRGN 5002
Alternative Names: PRGN-5002Latest Information Update: 28 Jul 2023
At a glance
- Originator Precigen Inc
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for research development in Solid-tumours in USA
- 01 Jun 2019 Early research in Solid tumours in USA before June 2019 (Precigen pipeline, July 2019)